Copart's relentless compounding potential and long-term growth prospects make it a valuable investment. Click to find out why ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

With its Bitcoin-in, Bitcoin-out model, Acre simplifies compounding for BTC holders while empowering decentralized networks ...

Earnings statements are a staple of corporate communications, a twice-yearly (or sometimes quarterly) opportunity for a ...

Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition ...

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...

Eli Lilly has reduced the price of its weight-loss drug, Zepbound, to combat competition from compounding pharmacies and Novo ...

The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

PayPal's earnings showed strong results, but were met with a sharp price correction. Read why the pullback presents a buying ...